Milestones

1. The line of research on impulsive-compulsive disorders is maintained through the third consecutive project awarded in the AES call of the ISCIII, which represents a continuation of the research on neuroinflammatory, neurocognitive, neuropsychological and neuroimaging markers in the short, medium and long term to identify predictive factors of response to treatment and relapse in patients with obsessive-compulsive disorder and gambling disorder (PI22/01183 continuation of PI19/01295 and PI16/00834, PI: Ángela Ibáñez)

2. The line of research on first psychotic episodes is maintained through the project P2022/BMD-7216 AGES 3-CM (Environment and Genes in Schizophrenia) of the program of Aid R & D in Biomedicine of the CAM and is expanded with participation in other funded projects (ICI21/00089 - SchizOMICS Project and 101030864 PMP21/00085 - FARMAPRED-PEP Project).

3. The relationship between human development and prevalence of deficit schizophrenia: Results from a systematic review and meta-analysis. Psychiatry Research. 2022: 317. FI: 11,225. Q1/D1.

4. Leadership of a Marie Sklodowska Curie European Grant of Excellence (H2020-MSCA-IF) entitled "Social exclusion as an acute psychosocial stressor in schizophrenia: impact on pathophysiology and social cognition (SimpSoCoS-101030864). 

5. The line of research on affective disorders has been strengthened through participation in 4 phase II and 1 phase III clinical trials with PIs from the group.